Acta Naturae
Acta Naturae is a new international journal on life sciences based in Moscow, Russia. Our goal is to present scientific work and discovery in molecular biology, biochemistry, biomedical disciplines and biotechnology. These fields represent the most important priorities for the research and engineering development both in Russia and worldwide. Acta Naturae is also a periodical for those who are curious in various aspects of biotechnological business, innovations in pharmaceutical areas, intellectual property protection and social consequences of scientific progress. The journal will publish analytical industrial surveys focused on the development of different spheres of modern life science and technology.
Being a radically new and totally unique publication in Russia, Acta Naturae will be useful to both representatives of fundamental research and experts in applied sciences.
The editorial council and editorial board include prominent scientists from Russia and abroad: Anatoly Grigoriev, Take Rolex vice-president of Russian Academy of sciences, Alexander Gabibov, Sergey Kochetkov, Patrick Masson, Alan Friboulet, Alfonso Tramontano, Knud Nierhaus.
The journal is published since April 2009, 4 times a year.
Announcements More Announcements...
Academician Anatoly I. Grigoriev passed away on February 11, 2023Posted: 17.02.2023
The editorial board of the journal Acta Naturae informs with deep regret that on February 11, 2023, the founder of the journal, the permanent chairman of the editorial board, academician Anatoly I. Grigoriev, passed away. |
|
|
Free Full Open Access to the jornalPosted: 30.10.2019
Journal “Acta Naturae” is now available in open access in PubMed Central and eLIBRARY.RU. |
|
|
Current Issue
Vol 16, No 4 (2024)
- Year: 2024
- Published: 09.12.2024
- Articles: 3
- URL: https://actanaturae.ru/2075-8251/issue/view/886
Reviews
Recombinant VSVs: A Promising Tool for Virotherapy
Abstract
Cancer is one of the leading causes of death worldwide. Traditional cancer treatments include surgery, radiotherapy, and chemotherapy, as well as combinations of these treatments. Despite significant advances in these fields, the search for innovative ways to treat malignant tumors, including the application of oncolytic viruses, remains relevant. One such virus is the vesicular stomatitis virus (VSV), which possess a number of useful oncolytic properties. However, VSV-based drugs are still in their infancy and are yet to be approved for clinical use. This review discusses the mechanisms of oncogenesis, the antiviral response of tumor and normal cells, and markers of tumor cell resistance to VSV virotherapy. In addition, it examines methods for producing and arming recombinant VSV and provides examples of clinical trials. The data presented will allow better assessment of the prospects of using VSV as an oncolytic.
4-14
Platforms for the Search for New Antimicrobial Agents Using In Vivo C. elegans Models
Abstract
Despite the achievements brought about by high-throughput screening technologies, there is still a lack of effective platforms to be used to search for new antimicrobial drugs. The antimicrobial activity of compounds continues, for the most part, to be assessed mainly using in vitro pathogen cultures, a situation which does not make easy a detailed investigation of the molecular mechanisms underlying host–pathogen interactions. In vivo testing of promising compounds using chordate models is labor-intensive and expensive and, therefore, is used in preclinical studies of selected drug candidates but not in primary screening. This approach does not facilitate the selection of compounds with low organ toxicity and is not suitable for the identification of therapeutic compounds that affect virulence factors. The use of microscopic nematode C. elegans to model human infections is a promising approach that enables one to investigate the host–pathogen interaction and identify anti-infective compounds with new mechanisms of action.
15-26
The Characteristics of the Metabolomic Profile in Patients with Parkinson’s Disease and Vascular Parkinsonism
Abstract
The gradually increasing age of the world population implies that the prevalence of neurodegenerative diseases also continues to rise. These diseases are characterized by a progressive loss of cognitive and motor functions. Parkinson’s disease, which involves the gradual death of specialized neural tissue, is a striking example of a neurodegenerative process. The pathomorphological analysis shows that chronic cerebral ischemia is accompanied by extensive complex neurodegeneration; parkinsonism is its clinical manifestation in 20–30% of cases. Although Parkinson’s disease and vascular parkinsonism are similar, these two pathologies have fundamentally different etiopathogeneses. But their set of differential diagnosis traits is confined to some features of the neurological status. There currently exist no diagnostic markers for individual neurodegenerative pathologies or the neurodegeneration phenomenon in general. Metabolomic profiling can be a promising means for finding a unique “fingerprint” of the disease. Identifying the biomarkers of various neurodegenerative diseases will help shorten the time to the diagnosis, forecast the course of the disease, and personalize the therapeutic approach. This review summarizes and compares the current concepts of metabolomics research into Parkinson’s disease and vascular parkinsonism, as well as the respective animal models.
27-37